Pediatrix Medical beats Q3 revenue estimates, raises FY adjusted EBITDA forecast

Pediatrix Medical

03/11/2025 11:08

Overview

Pediatrix Q3 revenue of about $493 mln beats analyst expectations

Adjusted EBITDA for Q3 beats estimates, driven by favorable reimbursement factors

Outlook

Pediatrix raises full-year 2025 Adjusted EBITDA outlook to $270 mln-$290 mln

Company cites healthcare environment changes and uncertainties impacting outlook

Result Drivers

REIMBURSEMENT FACTORS - CEO Mark S. Ordan attributes Q3 results to strong collection activity, higher patient acuity, and favorable payor mix

SAME-UNIT REVENUE GROWTH - Same-unit net revenue increased by 7.6%, driven by reimbursement factors and patient service volumes

PRACTICE DISPOSITIONS - Practice dispositions contributed to the increase in Adjusted EBITDA

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$492.87 mln
$476.49 mln (7 Analysts)
Q3 EPS
$0.84
Q3 Net Income
$71.70 mln
Q3 Adjusted EBITDA
Beat
$87.31 mln
$64.26 mln (6 Analysts)
Q3 Income from operations
$68.05 mln
Q3 Operating Expenses
$424.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $17.00, about 0.2% below its October 31 closing price of $16.97

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nBw4qjvwha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)